Develop a new drug for someone Who might be suffering somewhere in the world.
DESIGNING DRUG COMBINATION
FOR ORPHAN DISEASE PATIENTS
MORE ABOUT US ▶
-
THE MULTI-PRONGED APPROACH
Let's open up new markets and revenue streams by predicting
more than one promising indication for a drug candidate
at the early development stage. We are a specialized discovery team
with novel technologies and unique massive bio-pharmacological
data resources for discovering hidden possibilities of drugs.
-
DRUG COMBINATION
Two major causes of failure in clinical trials are lack of safety
(~45% failure rate in Phase I) and efficacy
(~65% failure rate in Phase II). A synergistic drug combination
increases the efficacy of the therapeutic
effect and reduces toxicity as a result of decreased dosage.
Using our unique Multi-Strategy Drug Repositioning System,
we will find the most synergistic drug partner that will target
multiple pathological networks with your drug.
-
ORPHAN DISEASE
In the process of researching for orphan diseases, one may
come across the problem of a lack of information.
That's where we step in. We can predict the pathological networks
and suggest suitable drugs for diseases, on which you may
have limited knowledge.
TECHNOLOGY
Our Special Technology
NEWS
Recent news & Event
DR.NOAH BIOTECH’s AI-driven ALS Medicine Receives U.S. FDA Approval for Phase 1 Clinical Trial IND
https://apnews.com/press-release/globenewswire-mobile/clinical-trials-u-s-food-and-drug-administration-986611bb972abf76b6b83bad19b05dc8By DR.NOAH BIOTECH Inc.Published 8:17 PM GMT+9, September 2, 2024SEOUL, KOREA, Sept. 02, 2024 (GLOBE NEWSWIRE) -- DR.NOAH BIOTECH (hereafter DR.NOAH), an AI-driven innovative drug development company, announced on August 23 that it had received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for Phase 1 clinical trial of a new drug combination (NDC-011) for Amyotrophic Lateral Sclerosis (ALS).This Phase 1 clinical trial is planned to be conducted at a specialized clinical trial institution in ...
MORE ABOUT US▶
DR. Noah Biotech’s phase 1 drug candidate developed by AI
Dr. Noah Biotech’s phase 1 drug candidate for stroke patients submitted for an IND application as the first example developed by AI… Series B expected to be revealed this year On July 22, Dr. Noah Biotech submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phase 1 drug candidate, ‘NDC-002,’ that helps recover from stroke developed by the artificial intelligence (AI) platform. With the AI platform, this bio-venture has focused on the development of new drugs specialized in neurological disorders. If the company obtains an approval of the IND application, ‘NDC-002’ would be regarded as the first example of t ...
MORE ABOUT US▶
New combinatory phrase 1 drug candidate, NDC-002, that helps reduce neuroinflammation and stimulate neuronal differentiation
Dr. Noah Biotech’s phrase 1 drug candidate for stroke patients submitted for an IND application as the first example developed by AINew combinatory phrase 1 drug candidate, NDC-002, that helps reduce neuroinflammation and stimulate neuronal differentiationDr. Noah Biotech announced that it submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phrase 1 drug candidate, ‘NDC-002’ that helps recover from stroke on July 22.The company said if it obtains an approval of the IND application, ‘NDC-002’ would be regarded as the first example of the new drug candidate developed by AI in Korea.Based on multiple mechanisms, th ...
MORE ABOUT US▶
Development of new drugs specialized for neurological disorders such as a stroke...Increasing the speed and efficiency of clinical trials by constructing own AI
[Interview of Bio CEO] CEO Jihyun Lee of DR.NOAH BIOTECH dreams of developing 'blockbuster'--going beyond the technology transfer of six pipelines[Medigate News Reporter Minji Seo] Neurological disorder is one of the complex disorders that are difficult to treat by controlling a single target. It is composed of complex mechanisms connected organically. A meaningful effect is achieved only by setting multiple targets. Considering such characteristics of the disorder, DR. NOAH BIOTECH is developing treatment with a strategy called 'combinatory drug.' The company is actively making use of the artificial intelligence (AI) platform developed to increase the efficiency of R&D pipelines.In add ...
MORE ABOUT US▶
The pharmaceutical industry is attracted by AI \"AI’s new medicine development occurs in succession.\"
AI allows the industry to save the time and costs of the new medicine development - competitive advantages in the marketDaewoong Pharmaceutical's subsidiary develops treatment for difficulty in hearing with an AI company specializing in new medicine developmentSK Chemical & Dr. Noah Biotech research and develop the AI new medicine together[Segye Biz = Correspondent Kim Min-ji] South Korea's pharmaceutical industry comes forward with new medicine development using artificial intelligence (AI) in full scale.If they use AI, they can drastically reduce the cost and time of research and development (R&D) for new medicine. The development of new medicine is a long-term project that requires more t ...
MORE ABOUT US▶
Dr. Noah’s “complex new drug for a stroke found by AI will have a clinical trial next year.”
"Doctor Noah will realize the possibility of developing a new drug using AI technology in the field of rare diseases."Lee Ji-hyun, CEO of Dr. Noah Biotech, said during the interview at the headquarters in Suwon. Dr. Noah Biotech (from now on referred to as Dr. Noah) is an AI new drug development venture. In particular, Dr. Noah's technology focuses on the discovery of complex substances fast. They also strive to develop their own complex for neurological diseases.They received KRW 1.5 billion funding in pre-series A in 2018 and KRW 4.5 billion funding in series A last August. It also attracted KRW 1 billion investment from JLK, which specializes in AI drugs. They have a short company history ...
MORE ABOUT US▶
Dr. Noah Biotech, SK Chemicals, AI-based new medicine development MOU
Build a pipeline for next-generation new medicine… Expected to develop treatments for incurable diseases through innovative new medicineDr. Noah Biotech (CEO Lee Ji-hyun), a company specializing in new medicine development based on artificial intelligence, announced on the 27th that it signed an "AI-based joint research and development agreement" with SK Chemicals.The main purpose of this agreement is to establish the pipeline of a next-generation new medicine through two companies’ cooperation and joint research based on the AI platform owned by Dr. Noah Biotech and ultimately develop an innovative complex drug.Dr. Noah Biotech is a startup that directly develops the treatment for neurolo ...
MORE ABOUT US▶
DR. NOAH BIOTECH CEO JI-HYUN LEE Giving Presentation at ‘THE AI KOREA 2020 Conference\'
DR. NOAH BIOTECH CEO JI-HYUN LEE gave a presentation titled Designing Drug Combinations for Orphan Diseases at ‘THE AI KOREA 2020 Conference’ held online on 27th.In its introductory remark, Ms. Lee said, "Our effort to incorporate AI technology into pharmaceutical development to increase efficiency and shorten the development period has continued up to now. In the global market, biotech companies, equipped with AI technology, are rubbing shoulders with multinational pharmaceuticals to develop new drugs with great success by attracting investment worth tens of and hundreds of billions of won. The country already saw more than ten AI companies jumping into the competition to bring a new drug ...
MORE ABOUT US▶
Dr. Noah Biotech, 4.5 billion KRW Series A “2 types of new drugs to undergo clinical trials next year”
Biospectator Journalist Jongwon JangBNH Investment, KB Investment, POSCO Capital, and T Investment as participants… R&D starting with stroke and amyotrophic lateral sclerosis medicine as well as DMD and SMADr. Noah Biotech has succeeded in attracting investments of 4.5 billion KRW for Series A. With these investments, Dr. Noah Biotech will complete preclinical studies on its leading products, stroke and amyotrophic lateral sclerosis (Lou Gehrig's disease) medicine, and will launch its first clinical trials next year. According to Dr. Noah Biotech on the 12th, KB Investment, POSCO Capital, and T Investment participated in the investment by taking over common shares under the lead of BN ...
MORE ABOUT US▶
AI technology-based system applied in rare disease treatment leads to the development of new treatments (Monthly People May 2020)
AI technology-based system applied in rare
disease treatment leads to the development of new treatments
Under a ‘pilot project to build bio-big
data for all ministries,’ promoted by three ministries including the Ministry
of Science and ICT, big data on genomic information, such as rare diseases, of
20,000 people is being established. With this, there is a growing interest in
developing medicines for rare diseases. Dr. Noa Biotech, a drug development
company that uses AI technology, continues to develop new drugs with focus on
rare disease treatment through its own platform.
◆ Development of Rare Disease Treatment Using
an Independent Platform
DR stands for doctor, as well as " ...
MORE ABOUT US▶
CONTACT
Direction
(16229) 경기도 수원시 영통구 창룡대로 256번길 91, 에이스광교타워2 1208호
(16229) ACE Gwanggyo Tower2 1208Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
Copyright © 2017 DR.NOAH BIOTECH All rights reserved.
Email. contact@drnoahbiotech.com | Tel. +82.31.546.1519 | Fax. +82.31.546.1529
(16229) ACE Gwanggyo Tower2 1208Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea